Answers are grounded in this paper and cite their sources.
S-SMEDDS enhances transdermal delivery of luliconazole, indicating a scalable solution for fungal infections.
The S-SMEDDS platform enhanced luliconazole solubility, transdermal delivery, and stability, offering a safe, effective, and scalable topical formulation for fungal infections and a practical route for industrial-scale production.
No takes yet. Share an insight, caveat, or question.
Kale et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: